Imunon, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Imunon, Inc. (Nasdaq: IMNN) on May 4, 2026, reporting events occurring on May 1, 2026. The filing addresses Item 5.02 regarding compensatory arrangements for certain officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on executive compensation terms.
Material Changes
On May 1, 2026, the Company entered into Change in Control (CIC) Agreements with three key executives following approval by the Compensation Committee:
- Stacy Lindborg (CEO and President)
- Douglas Faller (Chief Medical Officer)
- Susan Eylward (General Counsel and Corporate Secretary)
These agreements establish severance benefits triggered by a termination without cause or resignation for good reason within a specific window surrounding a change in control.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or general management commentary regarding business operations. The material details are as follows:
- Severance Multiplier: Dr. Lindborg is entitled to 2.5 times the sum of annual base salary and target annual bonus. Messrs. Faller and Ms. Eylward are entitled to 1.5 times the sum of annual base salary and target annual bonus.
- Health Benefits: Premiums for health and life insurance will be paid or reimbursed for up to 18 months post-termination (24 months for Dr. Lindborg).
- Equity Acceleration: Outstanding equity awards will fully accelerate. Options generally remain exercisable for the remainder of the original term.
- Conditions: Benefits are subject to the execution of a release of claims. Executives receive the greater of benefits under this agreement or any other existing agreement, without duplication.
Investor Verification Checklist
- Review the full text of the Change in Control Agreement attached as Exhibit 10.1 for specific definitions of "cause," "good reason," and "change in control."
- Verify the current annual base salary and target bonus amounts for the named executives to calculate potential severance liabilities.
- Assess the impact of full equity acceleration on the Company's dilution and cash burn in a potential acquisition scenario.
- Confirm if any other executive compensation agreements exist that might supersede or interact with these CIC Agreements.